{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:09:15Z","timestamp":1791270555530,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/cco.0000000000000048","type":"journal-article","created":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T08:42:24Z","timestamp":1389948144000},"page":"237-244","source":"Crossref","is-referenced-by-count":63,"title":["Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma"],"prefix":"10.1097","volume":"26","author":[{"given":"Auris O.","family":"Huen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210128","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(85)90275-2","article-title":"Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product.","volume":"42","author":"Anderson","year":"1985","journal-title":"Cell"},{"key":"R2-16-20210128","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0092-8674(00)80172-5","article-title":"The dorsoventral regulatory gene cassette spatzleTollcactus controls the potent antifungal response in drosophila adults.","volume":"86","author":"Lemaitre","year":"1996","journal-title":"Cell"},{"key":"R3-16-20210128","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2217\/imt.09.70","article-title":"Toll-like receptor agonists in cancer therapy.","volume":"1","author":"Adams","year":"2009","journal-title":"Immunotherapy"},{"key":"R4-16-20210128","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4161\/onci.20931","article-title":"Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"key":"R5-16-20210128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.smim.2006.12.004","article-title":"TLR signaling.","volume":"19","author":"Kawai","year":"2007","journal-title":"Semin Immunol"},{"key":"R6-16-20210128","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.","volume":"34","author":"Kawai","year":"2011","journal-title":"Immunity"},{"issue":"Pt 6","key":"R8-16-20210128","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1042\/BST0351461","article-title":"Synthetic agonists of Toll-like receptors 7, 8 and 9.","volume":"35","author":"Agrawal","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"R9-16-20210128","doi-asserted-by":"crossref","first-page":"e43320","DOI":"10.1371\/journal.pone.0043320","article-title":"Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells.","volume":"7","author":"Hackstein","year":"2012","journal-title":"PLoS One"},{"key":"R10-16-20210128","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1074\/jbc.M410592200","article-title":"Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus.","volume":"280","author":"Guillot","year":"2005","journal-title":"J Biol Chem"},{"key":"R11-16-20210128","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0163-7258(94)90023-X","article-title":"Coleys toxins, tumor necrosis factor and cancer research: a historical perspective.","volume":"64","author":"Wiemann","year":"1994","journal-title":"Pharmacol Ther"},{"key":"R12-16-20210128","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder.","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"R13-16-20210128","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience.","volume":"180","author":"Morton","year":"1974","journal-title":"Ann Surg"},{"key":"R15-16-20210128","first-page":"5176","article-title":"Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.","volume":"53","author":"Witt","year":"1993","journal-title":"Cancer Res"},{"key":"R16-16-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00403-004-0465-4","article-title":"Pharmacokinetics and safety of imiquimod 5 cream in the treatment of actinic keratoses of the face, scalp, or hands and arms.","volume":"296","author":"Harrison","year":"2004","journal-title":"Arch Dermatol Res"},{"key":"R17-16-20210128","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1258\/ijsa.2012.012076","article-title":"Local and systemic adverse effects of imiquimod therapy for external anogenital warts in men: report of three cases.","volume":"23","author":"Rosenblatt","year":"2012","journal-title":"Int J STD AIDS"},{"key":"R18-16-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.2008.08615.x","article-title":"A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.","volume":"159","author":"Szeimies","year":"2008","journal-title":"Br J Dermatol"},{"key":"R19-16-20210128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood-2011-05-355222","article-title":"In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 12 study.","volume":"119","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"R20-16-20210128","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/sj.jid.5700264","article-title":"Imiquimod for actinic keratosis: systematic review and meta-analysis.","volume":"126","author":"Hadley","year":"2006","journal-title":"J Investig Dermatol"},{"key":"R21-16-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1067\/mjd.2002.123492","article-title":"Clinical effect of imiquimod 5 cream in the treatment of actinic keratosis.","volume":"47","author":"Persaud","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R22-16-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40257-013-0023-y","article-title":"Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents.","volume":"14","author":"Samrao","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"R23-16-20210128","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5 cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology.","volume":"51","author":"Szeimies","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"R24-16-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2133.2007.08272.x","article-title":"Multicenter, open-label study using imiquimod 5 cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head.","volume":"157","author":"Stockfleth","year":"2007","journal-title":"Br J Dermatol"},{"key":"R25-16-20210128","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-2133.2009.09260.x","article-title":"Effect of dosing frequency on the safety and efficacy of imiquimod 5 cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.","volume":"161","author":"Gebauer","year":"2009","journal-title":"Br J Dermatol"},{"key":"R26-16-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaad.2008.08.039","article-title":"Placebo-controlled, double-blind, randomized pilot study of imiquimod 5 cream applied once per week for 6 months for the treatment of actinic keratosis.","volume":"60","author":"Zeichner","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"R27-16-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2133.2007.08269.x","article-title":"Topical immunomodulation under systemic immunosuppression: results of a multicenter, randomized, placebo-controlled safety and efficacy study of imiquimod 5 cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.","volume":"157","author":"Ulrich","year":"2007","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"R28-16-20210128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","article-title":"A randomized study of topical 5 imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.","volume":"157","author":"Krawtchenko","year":"2007","journal-title":"Br J Dermatol"},{"key":"R29-16-20210128","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra044151","article-title":"Basal-cell carcinoma.","volume":"353","author":"Rubin","year":"2005","journal-title":"N Engl J Med"},{"key":"R30-16-20210128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0190-9622(86)70192-8","article-title":"Treatment of basal cell carcinoma with intralesional interferon.","volume":"15","author":"Greenway","year":"1986","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 66","key":"R31-16-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.0366-077X.2003.05634.x","article-title":"Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5 cream or vehicle.","volume":"149","author":"Berman","year":"2003","journal-title":"Br J Dermatol"},{"key":"R32-16-20210128","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0190-9622(99)70261-6","article-title":"Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5 cream.","volume":"41","author":"Beutner","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R33-16-20210128","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1067\/mjd.2001.113689","article-title":"Imiquimod 5 cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.","volume":"44","author":"Marks","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R34-16-20210128","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1067\/mjd.2002.126215","article-title":"Imiquimod 5 cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.","volume":"47","author":"Geisse","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R35-16-20210128","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1365-2133.2002.05069.x","article-title":"Imiquimod 5 cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.","volume":"147","author":"Sterry","year":"2002","journal-title":"Br J Dermatol"},{"key":"R36-16-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2230.2004.01456.x","article-title":"Efficacy of imiquimod 5 cream for basal cell carcinoma in transplant patients.","volume":"29","author":"Vidal","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"R37-16-20210128","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1470-2045(13)70143-8","article-title":"Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, noninferiority, randomized controlled trial.","volume":"14","author":"Arits","year":"2013","journal-title":"Lancet Oncol"},{"key":"R38-16-20210128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CJI.0b013e318174a4df","article-title":"Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.","volume":"31","author":"Hofmann","year":"2008","journal-title":"J Immunother"},{"issue":"Suppl 66","key":"R40-16-20210128","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.0366-077X.2003.05637.x","article-title":"Treatment of lentigo maligna with topical imiquimod.","volume":"149","author":"Naylor","year":"2003","journal-title":"Br J Dermatol"},{"key":"R41-16-20210128","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/archderm.144.7.943","article-title":"Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients.","volume":"144","author":"Buettiker","year":"2008","journal-title":"Arch Dermatol"},{"key":"R42-16-20210128","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archdermatol.2012.270","article-title":"A randomized trial of the off-label use of imiquimod, 5, cream with vs. without tazarotene, 0.1, gel for the treatment of lentigo maligna, followed by conservative staged excisions.","volume":"148","author":"Hyde","year":"2012","journal-title":"Arch Dermatol"},{"key":"R43-16-20210128","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0889-8588(03)00109-6","article-title":"Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.","volume":"17","author":"Rook","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"R44-16-20210128","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaad.2009.12.052","article-title":"Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.","volume":"63","author":"Kim","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R45-16-20210128","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archderm.138.9.1137","article-title":"Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod.","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"R46-16-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaad.2004.04.049","article-title":"Treatment of patch and plaque stage mycosis fungoides with imiquimod 5 cream.","volume":"52","author":"Deeths","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R47-16-20210128","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1365-2230.2006.02208.x","article-title":"Treatment of mycosis fungoides with imiquimod 5 cream.","volume":"31","author":"Ariffin","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"R48-16-20210128","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3109\/10428194.2011.582202","article-title":"Synergistic enhancement of cellular immune responses by the novel Toll receptor 78 agonist 3M-007 and interferon-: implications for therapy of cutaneous T-cell lymphoma.","volume":"52","author":"Wysocka","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R49-16-20210128","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14760584.2013.811208","article-title":"The use of toll-like receptor 78 agonists as vaccine adjuvants.","volume":"12","author":"Vasilakos","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"R50-16-20210128","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/j.vaccine.2005.06.024","article-title":"TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848).","volume":"23","author":"Weeratna","year":"2005","journal-title":"Vaccine"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:55:28Z","timestamp":1620950128000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201403000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000048","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}